Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amarantus BioSciences has got notice of allowance (NOA) for its US patent application on discovery of mesencephalic astrocyte-derived neurotrophic factor (MANF).
Subscribe to our email newsletter
MANF is a potent neurotrophic factor which is used to treat apoptosis-related diseases including Parkinson’s disease.
Amarantus claims to protect its compositions of matter and methods of use for MANF, and other related compounds in the patent.
Amarantus BioSciences CEO Martin Cleary said the new patent will further protect its intellectual property as the company expands its pipeline of first-in-class therapeutics to address a number of indications.
The company said MANF is currently in pre-clinical development.